Tempus, the cancer fighting start up from extraordinary organizer Eric Lefkofsky, has a goal to give specialists at the University of Chicago, more detailed information on treating patients with breast cancer. Tempus declared an association with the University of Chicago Medicine Thursday in order to give atomic sequencing and investigation to UChicago’s breast cancer specialists. These findings will help them to provide the top individual care for their patients as well as hope for more positive outcomes. Tempus uses real time genomic sequencing to aid in these decisions regarding individual treatment packages. The startup, Tempus, was established in 2015. It is located at 600 W. Chicago, where Groupon, Lightbank, Drivin and Lekofsky’s different endeavors are found.
Eric Lefkofsky is the main supporter and CEO of Tempus. He is an establishing accomplice of Lightbank, a wander support putting resources into problematic innovations. As well as Uptake, EchoLoistics, and Inner Workings. In 2006 he created Lefkofsky Family Foundation with his wife, which is a charity foundation. Eric is also Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago.
Lefkofsky is a subordinate educator at the University of Chicago and creator of Accelerated Disruption. He moved on from the University of Michigan and got his Juris Doctor at University of Michigan Law School. He is a benefactor and Chairman of groupon, a worldwide web based business commercial center, and supporter of Uptake Technologies, a main prescient investigation stage for the world’s biggest companies like Mediaocean. To learn more please follow Lefkofsky on twitter at @lefkofsky and/or facebook at @eplefkofsky. You just have to find his profile at Eric Lefkofsky and you will be able to read his latest stories on the recent findings.
The 21st Century is full of innovation and innovators that have changed society for the better. Advanced Technology play a vital role in our everyday lives and the pharmaceutical industry is no exception. Have you ever heard of Dr. Clay Siegall? Did you know that he is leading one of the top companies of the medical field? Dr. Clay Siegall may not be a household name like your favorite celebrities, but he has done more for society than many of the celebrities combined and this is how he did it.
Founded in 1998, Seattle Genetics has come along way from it’s inception. The Bothell, Washington Biotechnology Company is changing lives for the better with it’s innovative products that fights cancer. The company has well over 600 employees and numerous high profile medicines on the market today. It’s flagship drug (ADCETRIS)is being used globally in over 60 different countries. These (ADCs) Antibody Drug Conjugates fights cancer by delivery cell-killing agents directly into the cells of this deadly illness. Seattle Genetics develops and commercializes these antibody based therapy products and there are many more in the company’s pipeline to look out for in the future. By using these products, cancer patients won’t receive those toxic effects that many chemotherapy styled medicines have on the body. This is why Seattle Genetics stand out among it’s peers in this challenging and competitive field.
President and (CEO) Clay Siegall is the guy in charge of this operation and he brings extensive high level knowledge to all of his company’s products. With a Ph.D in Genetics and a (BS) in Zoology, this scientist/doctor has the expertise, talent, skill, and capabilities to produce some of the highest quality cancer fighting medications to date. Before Seattle Genetics’ inception years ago, Dr. Siegall has worked with many prominent business’ in this field such as Bristol-Myers Squibb, National Institute of Health, and The National Cancer Society. Not keep bragging, but the good doctor has over 70 publications and currently holds up to 15 patents. With Dr. Clay Siegall in charge, the future looks much more brighter for cancer patients.